EZH2 is a clinically validated drug target in oncology and its inhibitors have been so far approved for follicular lymphoma and epithelioid sarcoma (Tazemetostat) or more recently also for adult T-cell leukemia/lymphoma (DS-3201/ Valemetostat)62. This evidence concerns the gene EZH2 and lymphoma.